



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.

VALNEVA

A European company (*Societas Europaea* or SE) with a Board of Directors

Share capital: €20,891,535.15

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Nantes

Companies Register (RCS) No. 422 497 560

COMPANY'S BOARD OF DIRECTORS AND GENERAL MANAGEMENT

(INCLUDING THE INFORMATION REQUIRED
PURSUANT TO ARTICLE R. 225-83, 5° OF THE FRENCH COMMERCIAL CODE,
CONSIDERING THE DRAFT RESOLUTION SUBMITTED TO THE GENERAL MEETING
FOR THE PURPOSE OF APPOINTING A NEW MEMBER OF THE BOARD OF DIRECTORS)

1. BOARD OF DIRECTORS

The Company's Board of Directors is currently composed of the following members:

- Ms. Anne-Marie Graffin, Chair of the Board of Directors;
- Mr. James Sulat, member of the Board of Directors;
- Mr. James Connolly, member of the Board of Directors;
- Bpifrance Participations SA, member of the Board of Directors (represented by Ms. Maïlys Ferrère);
- Ms. Kathrin Jansen, member of the Board of Directors; and
- Mr. Thomas Lingelbach, member of the Board of Directors and CEO (*Directeur Général*).

It is proposed to the shareholders of this Combined General Meeting to appoint Ms. Danièle Guyot-Caparros as a Company Director, for a three-year (3) term expiring at the end of the General Meeting called in 2027 to approve the financial statements of the fiscal year ending on December 31, 2026.



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Ms. Anne-Marie Graffin

CHAIR OF VALNEVA SE'S BOARD OF DIRECTORS
(63 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since July 5, 2013)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE	SCIENTIFIC COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	—	Chair since December 20, 2023	—	—	Experience as an executive in the vaccine industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Vetoquinol SA

- Board member, since September 2022

SMAG Consulting SAS

(formerly SARL SMAG Consulting)

- President, since April 2021, (previously Managing Director of the SARL, since September 2011)

Sartorius Stedim Biotech SA (*)

- Board member, since April 2015

Nanobiotix SA (*)

- Supervisory Board member, since January 2014

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

M2Care SAS

- Board member, from October 2019 to June 2022

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. James Sulat

VICE-CHAIR OF VALNEVA SE'S BOARD OF DIRECTORS
(73 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously Vice-Chair of the Company's Supervisory Board since May 28, 2013)

End of current term of office at the end of the General Meeting called in 2025 to approve the annual financial statements of the fiscal year ending on December 31, 2024

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE	SCIENTIFIC COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Chair since December 20, 2023	Member since December 20, 2023	—	—	Finance, Strategy, Capital Markets and Corporate Governance

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

GS Holdings, Inc.

- Member of the Board of Directors, since October 2021

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Mallinckrodt pic (*)

- Member of the Board of Directors, from June 2022 to November 2023
- Chair of the Audit Committee, from June 2022 to November 2023
- Member of the Compensation Committee, from June 2022 to November 2023

Excicure, Inc. (*)

- Member of the Board of Directors, from January 2021 to December 2022
- Chair of the Audit Committee, from January 2021 to December 2022

Arch Therapeutics, Inc.

- Member of the Board of Directors, from August 2015 to December 2021

AMAG Pharmaceuticals, Inc.

- Chair of the Compensation Committee, from May 2019 to November 2020
- Member of the Board of Directors, from April 2014 to November 2020
- Transactions Committee member, from April 2014 to November 2020
- Audit Committee member, from April 2014 to May 2019

Momenta Pharmaceuticals Inc.

- Member of the Board of Directors, from June 2018 to June 2019
- Audit Committee member, from June 2008 to June 2019
- Nominations and Corporate Governance Committee member, from June 2008 to June 2019

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. James Connolly

MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS
(59 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since June 23, 2022)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE	SCIENTIFIC COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	Member since December 20, 2023	Member since December 20, 2023	—	—	Commercial/ Marketing, Corporate Strategy, Finance, Business Development and Corporate Governance

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

- IAVI
- Member of the Board of Directors, since October 2018

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

- Covenant House Pennsylvania
- Member of the Board of Directors, from November 2013 to September 2023
- Ambulatus Robotics Inc.
- Member of the Board of Directors, from September 2020 to December 2021
- Tivorsan Pharmaceuticals, Inc.
- Member of the Board of Directors, from August 2015 to August 2020
- Vaxess Technologies, Inc.
- Member of the Board of Directors, from September 2013 to July 2019

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Ms. Mailys Ferrère

PERMANENT REPRESENTATIVE OF BPIFRANCE PARTICIPATIONS SA, MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS (61 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since June 23, 2022)

End of current term of office at the end of the General Meeting called in 2025 to approve the financial statements of the fiscal year ending on December 31, 2024

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE	SCIENTIFIC COMMITTEE	EXPERIENCE AND EXPERTISE
"Yes" under the Nasdaq rules, but "No" under the recommendations of the Middlednext Code ⁽¹⁾	Member since December 20, 2023	—	Member since December 20, 2023	—	—

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽²⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Permanent representative of Bpifrance Participations SA in its capacity as member of the Board of Directors of Devialet SA, since July 2022

Permanent representative of Bpifrance Participations SA in its capacity as member of the Strategic Committee of Doctolib SAS, since January 2023

DBV Technologies SA (*)

- Member of the Board of Directors, since June 2016

Bpifrance

- Manager of the Investment Division Large Venture, since November 2013

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

(1) See Section 2.2.5 of the Company's Universal Registration Document
(2) Current listed companies are indicated by (*).

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Permanent representative of Bpifrance Participations SA in its capacity as member of the Board of Directors of MWM SAS, from May 2020 to May 2023

Sequans Communications SA (*)

- Member of the Board of Directors, from June 2017 to March 2023

Permanent representative of Bpifrance Participations SA in its capacity as Supervisory Board member of Innate Pharma (*), from June 2017 to June 2021

Euronext Paris SA

- Member of the Board of Directors, from January 2016 to July 2021

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Ms. Kathrin Jansen

MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS
(66 ANS)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously a member of the Company's Supervisory Board since June 21, 2023)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending on December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE	SCIENTIFIC COMMITTEE	EXPERIENCE AND EXPERTISE
Yes	—	—	Member since December 20, 2023	Chair since December 20, 2023	More than three decades of vaccine R&D experience

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Pfizer Inc. (*)

- Senior Vice President and Head of Vaccine Research and Development, from June 2015 to July 2022

OTHER POSITIONS

VaxCo

- Scientific Advisor, since January 2024

Bill & Melinda Gates Foundation

- Scientific Advisor, since December 2023

Wistar Institute

- Strategic Advisor to the Director of the Vaccine and Immunotherapy Center, since January 2023

Pfizer Inc. (*)

- Consultant, since September 2022

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. Thomas Lingelbach

MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS — CEO (*DIRECTEUR GÉNÉRAL*)
(60 YEARS OLD)

First appointment to Valneva SE's Board of Directors by the Ordinary General Meeting on December 20, 2023 (previously Chair of the Company's Management Board since May 28, 2013, and President & CEO)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending December 31, 2025

INDEPENDENT	AUDIT, COMPLIANCE AND RISK COMMITTEE	NOMINATION, GOVERNANCE AND COMPENSATION COMMITTEE	ESG COMMITTEE	SCIENTIFIC COMMITTEE	EXPERIENCE AND EXPERTISE
No	—	—	Chair since December 20, 2023	Member since December 20, 2023	More than 30 years of experience in the vaccine industry

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

- Valneva France SAS
 - Supervisory Board member, since February 2019

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

- VBC 3 Errichtungs GmbH
 - Geschäftsführer, since October 2023
- Valneva UK Limited
 - Director, since October 2015
- Valneva Sweden AB
 - Chair of the Board, since February 2015
- Valneva Canada Inc.
 - Director, since January 2015
- Vaccines Holdings Sweden AB
 - Chair of the Board, since December 2014
- Valneva Austria GmbH
 - Geschäftsführer, since August 2013
- Valneva USA Inc.
 - CEO, since November 2012
 - Director, since August 2008
- Valneva Scotland Ltd.
 - Director, since December 2006

OTHER POSITIONS

—

(1) Current listed companies are indicated by (*).

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OTHER POSITIONS

—



MS. DANIÈLE GUYOT-CAPARROS

PROPOSAL FOR APPOINTMENT AS MEMBER OF THE BOARD OF DIRECTORS OF VALNEVA SE

Ms. Guyot-Caparros, aged 65, has a proven track record in finance and business operations. She started her career in Audit and Corporate Finance with PWC specializing in the Chemical/Pharma Industry. In 1992, she joined Rhône-Poulenc-Rorer (later Aventis and Sanofi) where she held several senior finance positions (CFO Global R&D, CFO Europe, Group Planning). She also held responsibilities in business development, pricing, and portfolio management.

In 2008, she became Senior Advisor for Deloitte France to support the development of the Life Sciences and Health Care Industry practice. She has supported multiple engagements with a large diversity of clients (big and mid-size pharma companies, biotech, foundations etc.) focusing on transformation, governance issues and M&A.

Ms. Guyot-Caparros is also an experienced non-executive director with a focus on Biotech/Medtech. From 2015 to 2017, she was board and audit committee member at Diaxonhit (now Eurobio Scientific) listed on Euronext Growth. She chaired the audit committee of Supersonic Imagine from July 2018 to September 2019 until the acquisition of the company by US group Hologic. From 2013 to June 2022, she chaired the audit committee of ONXEO (listed on Euronext, OMX Copenhagen and now Euronext Growth) and chaired the board from May 2019 to July 2021. In October 2022, she joined the board of DBV Technologies, a company listed on Euronext and Nasdaq, and is a member of the audit committee and of the compensation committee.

Ms. Guyot-Caparros is a graduate from ICN (Institut Commercial de Nancy), with specialization in finance and accounting. She holds a chartered accountant degree and a non-executive director qualification awarded by IFA-Science-Po.

Currently, Ms. Guyot-Caparros does not hold any shares of the Company Valneva SE.



2. GENERAL MANAGEMENT

The Company's General Management is currently composed of the following members:

- Mr. Thomas Lingelbach, CEO (*Directeur Général*);
- Mr. Franck Grimaud, Associate Managing Officer (*Directeur Général Délégué*);
- Mr. Frédéric Jacotot, Associate Managing Officer (*Directeur Général Délégué*);
- Mr. Juan Carlos Jaramillo, Associate Managing Officer (*Directeur Général Délégué*);
- Mr. Peter Bühler, Associate Managing Officer (*Directeur Général Délégué*);
- Ms. Dipal Patel, Associate Managing Officer (*Directrice Générale Déléguée*).

The CEO and the aforementioned Associate Managing Officers are members of the Executive Committee established by the Company, which also includes Mr. Vincent Dequenne, Chief Operating Officer, Ms. Petra Pesendorfer, Chief People Officer and Dr. Hanneke Schuitemaker, Chief Scientific Officer.



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. Thomas Lingelbach

MEMBER OF VALNEVA SE'S BOARD OF DIRECTORS — CEO (*DIRECTEUR GÉNÉRAL*)
MEMBER OF THE EXECUTIVE COMMITTEE
(60 YEARS OLD)

First appointment as *Directeur Général* of Valneva SE by the Board of Directors on December 20, 2023 (previously Chair of the Company's Management Board since May 28, 2013, and President & CEO)

End of current term of office at the end of the General Meeting called in 2026 to approve the annual financial statements of the fiscal year ending December 31, 2025

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- Supervisory Board member, since February 2019

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

VBC 3 Errichtungs GmbH

- *Geschäftsführer*, since October 2023

Valneva UK Limited

- Director, since October 2015

Valneva Sweden AB

- Chair of the Board, since February 2015

Valneva Canada Inc.

- Director, since January 2015

Vaccines Holdings Sweden AB

- Chair of the Board, since December 2014

Valneva Austria GmbH

- *Geschäftsführer*, since August 2013

Valneva USA Inc.

- CEO, since November 2012
- Director, since August 2008

Valneva Scotland Ltd.

- Director, since December 2006

OTHER POSITIONS

—

(1) Current listed companies are indicated by (*).

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OTHER POSITIONS

—



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. Franck Grimaud

ASSOCIATE MANAGING OFFICER (*DIRECTEUR GÉNÉRAL DÉLÉGUÉ*) & CHIEF BUSINESS OFFICER
MEMBER OF THE EXECUTIVE COMMITTEE
(58 YEARS OLD)

First appointment as a *Directeur Général Délégué* of Valneva SE by the Board of Directors on December 20, 2023 (previously a member of the Company's Management Board and Managing Director, according to the decision of the Supervisory Board dated May 10, 2013)

End of current term of office at the end of the General Meeting called in 2025 to approve the annual financial statements of the fiscal year ending December 31, 2024

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- Chair of the Supervisory Board, since June 2023

Small Consulting SASU

- President, since June 2022

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Austria GmbH

- *Prokurist*, since January 2024

Valneva Scotland Ltd.

- Director, since June 2017

Valneva USA Inc.

- Director, since December 2015
- Chief Business Officer, since December 2015

Valneva UK Limited

- Director, since October 2015

Valneva Sweden AB

- Board member, since February 2015

Valneva Canada Inc.

- Director, since January 2015

Vaccines Holdings Sweden AB

- Board member, since December 2014
- Managing Director, since December 2014

OTHER POSITIONS

Fonds Pays de la Loire Participations

- Chair of the Governing Board, since September 2016

Atlanpole Biothérapies

- President, since February 2018
- Board member, since January 2015

(1) Current listed companies are indicated by (*).

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

BliNK Biomedical SAS

- Strategic Committee member, since January 2015 to October 2023

Valneva France SAS

- President, from February 2019 to June 2023

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Austria GmbH

- *Geschäftsführer*, from August 2013 to January 2024

Valneva Canada Inc.

- President, from January 2015 to May 2023

Grimaud (Deyang) Animal Health Co Ltd.

- Board member, from September 2000 to February 2019

OTHER POSITIONS

—



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. Frédéric Jacotot

ASSOCIATE MANAGING OFFICER (*DIRECTEUR GÉNÉRAL DÉLÉGUÉ*) — GENERAL COUNSEL & CORPORATE SECRETARY
MEMBER OF THE EXECUTIVE COMMITTEE
(60 YEARS OLD)

First appointment as a *Directeur Général Délégué* of Valneva SE by the Board of Directors on December 20, 2023 (previously a member of the Company's Management Board since April 1, 2017)

End of current term of office: July 31, 2024

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- Member of the Supervisory Board, since February 2019

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Austria GmbH

- *Prokurist*, since January 2024

Valneva Sweden AB

- Board member, since June 2017

Vaccines Holdings Sweden AB

- Board member, since June 2017

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- Chair of the Supervisory Board, from February 2019 to June 2023

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Austria GmbH

- *Geschäftsführer*, from September 2017 to January 2024

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. Juan Carlos Jaramillo

ASSOCIATE MANAGING OFFICER (*DIRECTEUR GÉNÉRAL DÉLÉGUÉ*) – CHIEF MEDICAL OFFICER
MEMBER OF THE EXECUTIVE COMMITTEE
(53 YEARS OLD)

First appointment as a *Directeur Général Délégué* of Valneva SE by the Board of Directors on December 20, 2023 (previously a member of the Company's Management Board since October 1, 2020)

End of current term of office at the end of the General Meeting called in 2025 to approve the annual financial statements of the fiscal year ending December 31, 2024

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- Supervisory Board member, since November 2020

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Vaccines Europe, European Federation of Pharmaceutical Industry and Association (EFPIA)

- Vice President Board Member of Vaccines Europe's Executive Board, since November 2022

Valneva Austria GmbH

- *Geschäftsführer*, since November 2020

Valneva USA Inc.

- Director, since November 2020

Valneva Sweden AB

- Board member, since October 2020

(1) Current listed companies are indicated by ^(*).

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Canada Inc.

- Member of the Board of Directors, from December 2020 to January 2024

Daiichi Sankyo GmbH

- Senior Vice-President, Head of Market Access & Pricing, from April 2017 to September 2020



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Mr. Peter Bühler

ASSOCIATE MANAGING OFFICER (DIRECTEUR GÉNÉRAL DÉLÉGUÉ) – CHIEF FINANCIAL OFFICER
MEMBER OF THE EXECUTIVE COMMITTEE
(54 YEARS OLD)

First appointment as a *Directeur Général Délégué* of Valneva SE by the Board of Directors on December 20, 2023 (previously a member of the Company's Management Board since January 1, 2022)

End of current term of office at the end of the General Meeting called in 2025 to approve the annual financial statements of the fiscal year ending December 31, 2024

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- *Directeur Général Délégué*, since January 2024

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Canada Inc.

- Director, since January 2024

Valneva USA Inc.

- Director, since January 2024

Valneva UK Limited

- Director, since January 2024

Vaccines Holdings Sweden AB

- Board member, since January 2024

Valneva Scotland Ltd.

- Director, since January 2024

VBC 3 Errichtungs GmbH

- *Geschäftsführer*, since October 2023

Valneva Austria GmbH

- *Geschäftsführer*, since January 2022

Valneva Sweden AB

- Board member, since January 2022

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Alba Bioscience Ltd.

- Member of the Board of Directors, from May 2021 to November 2021

Quotient Biocampus Ltd.

- Member of the Board of Directors, from May 2021 to November 2021

QBD (QS IP) Ltd.

- Member of the Board of Directors, from January 2021 to November 2021

Quotient Ltd.

- Chief Financial Officer, from February 2020 to December 2021

Quotient Suisse SA

- Member of the Board of Directors, from January 2020 to September 2021

Zaluvida AG

- Chief Financial Officer, from April 2017 to March 2019

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.



Ms. Dipal Patel

ASSOCIATE MANAGING OFFICER (*DIRECTRICE GÉNÉRALE DÉLÉGUÉE*) – CHIEF COMMERCIAL OFFICER
MEMBER OF THE EXECUTIVE COMMITTEE
(50 YEARS OLD)

First appointment as a Directrice Générale Déléguée of Valneva SE by the Board of Directors on December 20, 2023 (previously a member of the Company's Management Board since November 17, 2022)

End of current term of office at the end of the General Meeting called in 2025 to approve the annual financial statements of the fiscal year ending December 31, 2024

OFFICES AND POSITIONS CURRENTLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE⁽¹⁾

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

Valneva France SAS

- President, since June 2023

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

Valneva Austria GmbH

- Prokurist, since January 2024

Valneva USA Inc.

- Director, since June 2023

Valneva Sweden AB.

- Director, since June 2023

Valneva Canada Inc.

- President, since May 2023

Valneva UK Limited

- Director, since November 2022

Lateral Pharma Pty Ltd

- Non-executive Director, since March 2021

OTHER POSITIONS

—

OFFICES AND POSITIONS PREVIOUSLY HELD IN ANY COMPANY OTHER THAN VALNEVA SE (IN THE LAST FIVE YEARS)

COMPANIES INCORPORATED UNDER AND GOVERNED BY FRENCH LAW

—

COMPANIES INCORPORATED UNDER AND GOVERNED BY THE LAW OF OTHER COUNTRIES

—

OTHER POSITIONS

—

(1) Current listed companies are indicated by (*).



VALNEVA SE - BOARD OF DIRECTORS AND GENERAL MANAGEMENT

This document is a free translation. In case of discrepancy between the French and the English version, the French version shall prevail.

OTHER EXECUTIVE COMMITTEE MEMBERS



Mr. Vincent Dequenne

CHIEF OPERATING OFFICER



Ms. Petra Pesendorfer

CHIEF PEOPLE OFFICER



Dr. Hanneke Schuitemaker

CHIEF SCIENTIFIC OFFICER